Participants will be randomized 1:1:1 to CRV-101 Vaccine high antigen dose, CRV-101 Vaccine low antigen dose, or Shingrix. Both study vaccines, CRV-101 Vaccine and Shingrix will be administered by intramuscular injection on Month 0 and Month 2. Safety, reactogenicity, and immunogenicity analysis will be performed overall and by age group of 50 to <60, 60 to <70, and ≥70 years of age. Participants will be followed for safety, immunogenicity, and herpes zoster cases, from Day 0 to the main study end (Month 14), and through the LTFU extension period (LTFU year 2, 3, 4, 5, 6).
The purpose of this study is to assess the safety and immunogenicity of CRV-101, an investigational vaccine compared to Shingrix for the prevention of herpes zoster in adults aged 50 years and older